Table 2.
Estimates of median overall survival (OS) and hazard ratio using the modified-iKM algorithm based on data extracted using different software (R: R package IPDfromKM, D: DigitizeIt, S: ScanIt), in comparison to published results (Report) in the POLAR trial
| Median OS | Hazard Ratio | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Arm | n | Report | R | D | S | Report | R | D | S | ||
| 1 | Atezolizumab | 24 | 15.5 | 15.5 | 15.5 | 15.5 | 0.49 | 0.48 | 0.46 | 0.45 | ||
| Docetaxel | 23 | 11.1 | 11.1 | 11.1 | 11.1 | |||||||
| 2 | Atezolizumab | 50 | 15.1 | 15.3 | 15.3 | 15.3 | 0.54 | 0.54 | 0.56 | 0.53 | ||
| Docetaxel | 55 | 7.4 | 7.6 | 7.4 | 8.1 | |||||||
| 3 | Atezolizumab | 93 | 15.5 | 15.3 | 15.5 | 15.7 | 0.59 | 0.59 | 0.58 | 0.59 | ||
| Docetaxel | 102 | 9.2 | 9.3 | 9.2 | 9.6 | |||||||
| 4 | Atezolizumab | 51 | 9.7 | 9.7 | 9.7 | 9.5 | 1.04 | 1.06 | 0.99 | 1.03 | ||
| Docetaxel | 41 | 9.7 | 9.7 | 9.7 | 9.8 | |||||||
| 5 | Atezolizumab | 144 | 12.6 | 13.3 | 12.4 | 12.3 | 0.73 | 0.72 | 0.70 | 0.72 | ||
| Docetaxel | 143 | 9.7 | 9.7 | 9.7 | 9.8 | |||||||
Group 1: TC3 or IC3; 2: TC2/3 or IC2/3; 3: TC1/2/3 or IC1/2/3; 4: TC0 or IC0; 5: all patients. The value of n refers to sample size